Biogen (BIIB)
(Delayed Data from NSDQ)
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$185.68 USD
+0.90 (0.49%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Top Research Reports for McDonald's, Thermo Fisher & Caterpillar
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Thermo Fisher (TMO) and Caterpillar (CAT).
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
by Zacks Equity Research
Earnings releases and key data-read outs were the key developments in the biotech sector last week.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook
by Zacks Equity Research
Alkermes (ALKS) surpasses earnings and sales expectations in the third quarter of 2018 and raises its financial guidance for 2018.
Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines
by Zacks Equity Research
Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.
Biogen (BIIB) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beat estimates both for earnings and sales in Q3. Its newest drug Spinraza performed well in the quarter.
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Alkermes Boasts Strong Portfolio and Impressive Pipeline
by Zacks Equity Research
Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.
Biogen (BIIB) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Corium's (CORI) Shares Surge on Merger Agreement With Gurnet
by Zacks Equity Research
Corium International (CORI) announces merger agreement with Gurnet Point Capital. The deal values Corium at $12.50 per share in cash and will take the company private.
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
by Zacks Equity Research
Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
Novartis Presents Data on Multiple Sclerosis Drug Gilenya
by Zacks Equity Research
Novartis (NVS) announces encouraging data from a late-stage trial, ASSESS, on multiple sclerosis drug, Gilenya, which further reinforces its efficacy in treating relapses.
The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altria, U.S. Bancorp, Biogen, Ecolab and HSBC
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatment.
Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status
by Zacks Equity Research
Data presentations by leading sector players take center stage this week.
Top Analyst Reports for Altria, U.S. Bancorp & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Altria (MO), U.S. Bancorp (USB) and Biogen (BIIB).
Novartis' Applications for MS Drug Accepted by FDA & EMA
by Zacks Equity Research
Novartis (NVS) progresses with its MS candidate, siponimod, as both the FDA and the EMA accepts the applications for the drug.
Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam
by Zacks Equity Research
Roche (RHHBY) reports encouraging data from two pivotal studies -- FIREFISH and SUNFISH -- on risdiplam for the treatment of Spinal Muscular Atrophy.
3 Biotech Stocks With Rising Estimates in the Past Month
by Zacks Equity Research
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
3 Drug/Biotech Stocks in Focus on World Alzheimer's Day
by Zacks Equity Research
We take a look at companies with prospective Alzheimer's Disease candidates in pipeline on World Alzheimer's Day.
The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works
Top Research Reports for Wells Fargo, Schlumberger & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Schlumberger (SLB) and Biogen (BIIB).
Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
by Zacks Equity Research
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo
by Zacks Equity Research
Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.